USPTO serial 79275945
DARNITSA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 12, 2021
- Examiner
- BUONGIORNO,CHRISTOPHER L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with DARNITSA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
UA
Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
UA
Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
UA
Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
UA
UA
UA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kenneth Motolenich-Salas
Kenneth Motolenich-Salas Hickman Becker Bingham Ledesma LLP99 Almaden Blvd., Suite 600San Jose, CA 95113UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antiseptics; vaccines; veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vitamin preparations; disinfectants; diagnostic preparations for veterinary purposes; diagnostic preparations for medical purposes; dietetic beverages adapted for medical purposes; Dietetic foods and beverages adapted for medical use; dietetic foods adapted for medical purposes; plant extracts for pharmaceutical purposes; herbal extracts for medical purposes; Capsules sold empty for pharmaceuticals; medicinal preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Drugs for medical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medicinal drinks; medicinal oils; medicated toiletry preparations; medicated shampoos; ointments for pharmaceutical purposes, namely, medicated ointments for treating dermatological conditions and antibiotic ointments; teeth filling material; medicinal alcohol; food supplements; medical dressings; nutritional supplements; Pre-filled syringes containing pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Air purifying preparations; food for babies; protein dietary supplements; Tissues impregnated with pharmaceutical lotions for treating dermatological conditions; Alcohol for pharmaceutical purposes; stem cells for medical purposes; transplants, namely, surgical implants comprising living tissue used in transplant operations; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; ferments for pharmaceutical purposes; phytotherapy preparations for medical purposes; chemico-pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical preparations for medical purposes for the diagnosis of pregnancy; Chemical preparations for pharmaceutical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical reagents for medical or veterinary purposes; surgical glues; surgical dressings; candy, medicated; candy for medical purposes; sanitary preparations for medical purposes; plasters for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
- Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
- Other trademarks owned by PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
- Other trademarks owned by Zahorii Hlib Volodymyrovych
- Other trademarks owned by Zahorii Hlib Volodymyrovych
- Other trademarks owned by Zahorii Hlib Volodymyrovych
- Other trademarks in Class 005
- Similar marks named DARNITSA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 12, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 3, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 3, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 3, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 3, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 30, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 13, 2021 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Apr 13, 2021 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Apr 12, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 12, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 18, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 27, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 27, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 25, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 7, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 7, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 7, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 21, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 21, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 21, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 21, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 21, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 3, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 3, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 3, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 3, 2020 | ALIE | ASSIGNED TO LIE | — |
| Aug 13, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 12, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 13, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 13, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 14, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 14, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 13, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 10, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 9, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |